MirimGENE's target of focus includes WARS among human aminoacyl-tRNA synthetase (ARSs). WARS, tryptophanyl-tRNA synthetase secreted from monocytes, is provided as a primary defense system against infection published in Nature Microbiology. If hyperactivated WARS is blocked, autoimmune diseases such as rheumatoid arthritis can be treated based on animal POC data. Activation of reduced WARS in immunosuppressive patients will cure various infectious diseases like sepsis and tuberculosis from hypo-immune status. MirimGENE's antibody biologics have been developed based on animal POC data and upstream/downstream processed in collaboration with Samsung Biologics. In 2024, GLP data are due to be generated then the application of IND for the Clinical Phase 1 trial will follow.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2019
Main Therapeutic Focus:
Immunology
Lead Product in Development:
Antibody for Rheumatoid Arthritis treatment
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
